These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23450519)

  • 41. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.
    Busby LT; Weyman A; Rodgers GM
    Am J Hematol; 2001 May; 67(1):54-6. PubMed ID: 11279659
    [TBL] [Abstract][Full Text] [Related]  

  • 42. My doctor prescribed a brand-name drug, but the pharmacist filled the prescription with a generic version. Will the generic work, and is it safe?
    Rosen DS
    Health News; 2001 Mar; 7(3):10. PubMed ID: 11263084
    [No Abstract]   [Full Text] [Related]  

  • 43. A Rare Case of Enoxaparin-Induced Skin Necrosis Without Thrombocytopenia.
    Li J; Inwald G; Thomas M
    Am J Phys Med Rehabil; 2019 May; 98(5):e51. PubMed ID: 30252691
    [No Abstract]   [Full Text] [Related]  

  • 44. Low-molecular-weight heparin-induced skin necrosis: a potential association with pre-existent hypercoagulable states.
    Toll A; Gallardo F; Abella ME; Fontcuberta J; Barranco C; Pujol RM
    Int J Dermatol; 2005 Nov; 44(11):964-6. PubMed ID: 16336536
    [No Abstract]   [Full Text] [Related]  

  • 45. Enoxaparin-induced reversible pancytopenia.
    Sari I; Davutoglu V
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):453-4. PubMed ID: 17911201
    [No Abstract]   [Full Text] [Related]  

  • 46. What's the problem with generic antiepileptic drugs?: a call to action.
    Berg MJ
    Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211
    [No Abstract]   [Full Text] [Related]  

  • 47. Enoxaparin in acute coronary syndromes.
    Lee S; Gibson CM
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):387-99. PubMed ID: 17489664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticoagulants and skin necrosis.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1994; 13(3):157-67. PubMed ID: 7827224
    [No Abstract]   [Full Text] [Related]  

  • 49. Antiepileptic drugs: the drawbacks of generic substitution.
    Lancet Neurol; 2010 Mar; 9(3):227. PubMed ID: 20170834
    [No Abstract]   [Full Text] [Related]  

  • 50. Generic anti-arrhythmic drugs.
    Obel IW
    Cardiovasc J S Afr; 2002; 13(3):131; author reply 132-3. PubMed ID: 12193966
    [No Abstract]   [Full Text] [Related]  

  • 51. Lessons learned in Reno.
    Contillo C
    Am J Nurs; 2011 Jan; 111(1):11. PubMed ID: 21191208
    [No Abstract]   [Full Text] [Related]  

  • 52. Extensive skin necrosis induced by low-molecular-weight heparin in a patient with systemic lupus erythematosus and antiphospholipid syndrome.
    Yazbek MA; Velho P; Nadruz W; Mahayri N; Appenzeller S; Costallat LT
    J Clin Rheumatol; 2012 Jun; 18(4):196-8. PubMed ID: 22647862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bioequivalence and narrow therapeutic index drugs.
    Benet LZ; Goyan JE
    Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Are generic drugs really inferior medicines?
    Moore N; Berdaï D; Bégaud B
    Clin Pharmacol Ther; 2010 Sep; 88(3):302-4. PubMed ID: 20725079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low-molecular-weight heparin-associated fat necrosis of the breast.
    Das AK
    Age Ageing; 2005 Mar; 34(2):193-4. PubMed ID: 15713870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Preventable problems in thyroid hormone substitution therapy. The risks of brand change are unpredictable].
    MMW Fortschr Med; 2010 Jun; 152(22):46-7. PubMed ID: 20590034
    [No Abstract]   [Full Text] [Related]  

  • 57. Bullous hemorrhagic dermatosis probably associated with enoxaparin.
    Miguel-Gomez L; Fonda-Pascual P; Carrillo-Gijon R; Muñoz-Zato E
    Indian J Dermatol Venereol Leprol; 2016; 82(3):319-20. PubMed ID: 27088940
    [No Abstract]   [Full Text] [Related]  

  • 58. Systemic bleeding in a patient with enoxaparin-induced thrombocytopenia.
    Famularo G; Gasbarrone L; Minisola G; De Simone C
    Am J Emerg Med; 2009 Jul; 27(6):756.e1-2. PubMed ID: 19751647
    [No Abstract]   [Full Text] [Related]  

  • 59. When do differences in dissolution profiles predict clinical problems?
    Ngo SN
    J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660
    [No Abstract]   [Full Text] [Related]  

  • 60. [Enoxaparin-induced reversible pancytopenia].
    Rangel Selvera OA; Gómez-Pavón J; Ruiperez Cantera I
    Rev Esp Geriatr Gerontol; 2013; 48(3):143-4. PubMed ID: 23481037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.